61 results on '"Kapiteijn, E."'
Search Results
2. 849P Time from primary melanoma to first distant recurrence in relation to survival outcomes in metastatic melanoma
3. 791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
4. 859P The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
5. 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)
6. 812P Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
7. 860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
8. P71 The Development of a Flexible and Easy to Tailor Disease Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma by Combining Trial and Real-World Data
9. POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies
10. POSB361 Quality of Life in Advanced Melanoma Patients in the Era of Novel Immuno- and Targeted Therapies
11. POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma
12. 23P A comprehensive analysis of the mucosal melanoma immune microenvironment
13. Time trends in treatment strategies and survival of older versus younger patients with synchronous metastasized melanoma – a population-based study in the Netherlands Cancer Registry
14. Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
15. 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial
16. 1018P Characterization of liver function tests following tebentafusp in phase III randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma (mUM)
17. 1750P Molecular genotyping in refractory thyroid cancers: Results of a European survey
18. 1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
19. 1070P Adjuvant treatment for melanoma in clinical practice: Trial versus reality
20. Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry
21. 37P First-line BRAF/MEK-inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: A propensity-matched survival analysis
22. 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
23. 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
24. 1120P Post-approval trials versus patient registries: Comparability of advanced melanoma patients with brain metastases
25. 1919P Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
26. 1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy
27. 1200P Tyrosine kinase activity profiling as a predictive biomarker for clinical benefit to immune checkpoint inhibition in advanced melanoma and NSCLC
28. 1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma
29. Treatment strategies and overall survival for incurable metastatic colorectal cancer – A EURECCA international comparison including 21,196 patients from the Netherlands and Norway
30. PCN501 VALUE FOR MONEY IN METASTATIC CUTANEOUS MELANOMA: DO BENEFITS OUTWEIGH THE COSTS OF NOVEL DRUGS?
31. PCN497 A NATIONWIDE COST OF ILLNESS STUDY OF METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS
32. Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
33. ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
34. P2.04-06 Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC
35. Health-related quality of life of advanced melanoma survivors treated with CTLA-4 immune checkpoint inhibition: A matched cohort study
36. Quality of life after curative resection for rectal cancer in patients treated with adjuvant chemotherapy compared with observation: results of the randomized phase III SCRIPT trial
37. Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options
38. PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS
39. A noninferiority trial of cabozantinib (C) comparing 60 mg vs 140 mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)
40. Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
41. ILLUMINATE 301: A randomized phase III comparison of IMO-2125 with ipilimumab (ipi) versus ipi alone in subjects with anti PD 1 refractory melanoma
42. Healthcare Costs of Ipilimumab in Patients with Advanced Cutaneous Melanoma in Dutch Clinical Practice
43. Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma
44. Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial
45. Late physical, psychological and social consequences of ipilimumab treatment in advanced melanoma
46. Informal Care and Productivity Losses are Important in Advanced Cutaneous Melanoma: Results of the Dutch Melanoma Treatment Registry
47. Quality of Life in Advanced Melanoma: Results of The Dutch Melanoma Treatment Registry
48. External Validity at Stake in Mapping Non-Preference Based Disease Specific Measures to Generic Preference-Based Utility Values in Advanced Cutaneous Melanoma
49. Survival in BRAF-mutant metastatic melanoma in the real-world setting: results from the Dutch Melanoma Treatment Registry
50. The influence of old age on everolimus exposure in patients with cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.